Mutant fragments of OspA and methods and uses relating thereto

US10544194B2 · kind B2 · utility

Assignee

• Valneva Austria GmbH · AT

Inventors

• Pär Comstedt · Wien, AT
• Urban Lundberg · Wien, AT
• Andreas Meinke · Pressbaum, AT
• Markus Hanner · Pressbaum, AT
• Wolfgang Schüler · Wien, AT
• Benjamin Wizel · Rockville, US
• Christoph Reinisch · Siegenfeld, AT
• Brigitte Grohmann · Perchtoldsdorf, AT
• Robert Schlegl · Siegenfeld, AT

Key dates

• Filing date: Sep 22, 2016
• Grant date: Jan 28, 2020
• Expiry date: Sep 22, 2036

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.